Aurinia Pharmaceuticals Inc

AUPH

Healthcare|Biotechnology|Canada

$15.79

-0.81 (-4.88%)

DCF (FCF)

$1.77

Tangible Book

$4.31

Graham Number

$14.51

Clinical Trials (20)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07611214 PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis	Lupus Nephritis	P4	Recruiting	150	Open-label	LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA), corticosteroid
NCT07596901 Study of Aritinercept in Patients With Generalized Myasthenia Gravis	Myasthenia Gravis, Generalized	P1P2	Recruiting	81	RCT, Double-blind	Aritinercept
NCT05962788 Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis	Adolescent Lupus Nephritis, Pediatric Lupus Nephritis	P3	Terminated	4	Open-label	voclosporin
NCT00258713 A 36-Week Extension to Protocol ISA04-03	Psoriasis	P3	Completed	309	RCT, Double-blind	voclosporin
NCT03597464 Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin	Lupus Nephritis	P3	Completed	216	RCT, Double-blind	Voclosporin, Placebo Oral Capsule
NCT05288855 Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis	Adolescent Lupus Nephritis, Pediatric Lupus Nephritis	P3	Terminated	9	RCT, Double-blind	Voclosporin, Placebo Oral Capsule
NCT00244842 Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis	Psoriasis	P3	Completed	451	RCT, Double-blind	voclosporin, Placebo
NCT01586845 Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation	Renal Transplantation	P3	Withdrawn	—	RCT, Single-blind	voclosporin, tacrolimus
NCT04147650 Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome	Dry Eye Syndrome, Keratoconjunctivitis Sicca	P2P3	Completed	508	RCT, Double-blind	0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution
NCT00408187 Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients	Psoriasis	P3	Completed	642	RCT, Double-blind	voclosporin, Ciclosporin, Placebo
NCT03021499 Aurinia Renal Response in Active Lupus With Voclosporin	Lupus Nephritis	P3	Completed	358	RCT, Double-blind	Voclosporin, Placebo Oral Capsule
NCT02949973 Aurinia Early Urinary Protein Reduction Predicts Response	Lupus Nephritis	P2	Completed	10	Open-label	voclosporin
NCT03597139 Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease	Dry Eye	P2	Completed	100	RCT, Single-blind	Voclosporin Ophthalmic Solution, Restasis®
NCT03598036 Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis	Focal Segmental Glomerulosclerosis	P2	Terminated	5	Open-label	Voclosporin
NCT02141672 AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)	Lupus Nephritis	P2	Completed	265	RCT, Double-blind	Voclosporin High Dose, Voclosporin Low Dose, Placebo
NCT04701528 Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients	Covid19, Kidney Transplant Infection	P2	Completed	20	RCT, Open-label	Voclosporin, Tacrolimus
NCT00270634 Study of ISA247 (Voclosporin) in De Novo Renal Transplantation	Kidney Diseases	P2	Completed	334	RCT, Open-label	Voclosporin, tacrolimus
NCT02949999 Voclosporin in Healthy Japanese Volunteers	Volunteers	P1	Completed	40	RCT, Double-blind	Voclosporin
NCT05306379 Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin	Drug-drug Interaction	P1	Completed	24	Open-label	Simvastatin, Voclosporin
NCT05337124 A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US	Lupus Nephritis		Completed	229	—	LUPKYNIS